普洛藥業(000739.SZ):安徽生物通過EDQM官方認證
格隆匯5月7日丨普洛藥業(000739.SZ)公佈,近日,公司下屬孫公司安徽普洛生物科技有限公司(以下簡稱“安徽生物”)通過了歐洲藥品質量管理局(以下簡稱“EDQM”)的官方現場檢查並獲得了EDQM檢查證書和硫酸粘菌素(原料藥)的CEP證書。
本次EDQM官方認證的順利通過,顯示了安徽生物產品質量和生產管理能力得到了歐洲規範市場的認可,標誌着該產品取得了歐洲市場銷售資質,有利於公司進一步拓展國際市場,對未來經營業績有一定積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.